BÖLÜM 20

MİDENİN NÖROENDOKRİN TÜMÖRLERİ VE NADİR MALİGN TÜMÖRLERİ

Mustafa Suphi TURGUT [1]

1. MİDENİN NÖROENDOKRİN TÜMÖRLERİ

Gastrointestinal sistem ve pankreastan kaynaklanan sindirim sisteminin Nöroendokrin Neoplasmları (NEN) nispeten nadirdir. Amerika Birleşik Devletleri'ndeki yıllık insidans, 100.000 nüfus başına yaklaşık 3,56'dır (1,2).

NEN'lerin sınıflandırılması ve isimlendirilmesi karmaşık ve kafa karıştırıcıdır. Çünkü çoğu çalışma belirli bir organ sisteminde ortaya çıkan tümörlere odaklanmıştır. Dünya Sağlık Örgütü (WHO) tarafından NEN'lerin sınıflandırılması için ortak bir çerçeve önerilmiştir (1,3). Ancak farklı organ sistemleri için WHO sınıflandırmalarında güncellemeler beklenmektedir. Bu nedenle, şimdilik kökenden bağımsız olarak tüm NEN'ler için uygun olan tek bir isimlendirme, derecelendirme veya evreleme sistemi yoktur. Bununla birlikte, tümörün proliferatif hızı ve lokal yayılma derecesi gibi özellikler çoğu sınıflandırma sistemi tarafından paylaşılmaktadır. NEN'ler için önerilen sınıflandırma sistemi WHO tarafından gastroenteropankreatik (GEP) sistemi için resmi olarak onaylanmıştır (1,4). Bir zamanlar gastrik karsinoidler olarak adlandırılan gastrik nöroendokrin tümörler (NET'ler), mide mukozasının enterokromaffin benzeri hücrelerinden

[1] Op. Dr., Sağlık Bilimleri Üniversitesi Erzurum Bölge Eğitim ve Araştırma Hastanesi Genel Cerrahi AD. Cerrahi Onkoloji BD., msturgutcerrah@gmail.com

İmmünohistokimyada insan gastrik müsin ve mitokondri için pozitif boyama ve H+-K+-ATPase ekspresyonu olmadığı görülmüştür. Bu nedenle, H+-K+-Atpaz'ın parietal gastrik hücre farklılaşmasının bir belirteci olduğu düşünüldüğünden, parietal hücreli karsinom yerine onkositik karsinom isimlendirmesinin kullanılmasını önerilmiştir. Bazı yazarlar tümör hücrelerinde proton pompasının pozitif boyanmasını tespit etmişlerdir (43). Tabukonun çalışmasında 10 hastanın 8 ine gastrektomi,1 ine EMR, 1 ine lazer uygulanmıştır (42).

KAYNAKLAR

1. Uptodate (2021). Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system 2021. (03.08.2021 tarihinde https://www.uptodate.com/contents/pathology-classification-and-grading-of-neuroendocrine-neoplasms-arising-in-the-digestive-system?search=Pathology,%20classification,%20and%20grading%20of%20neuroendocrine%20neoplasms%20arising%20in%20the%20digestive%20system&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1 adresinden ulaşılmıştır).
2. Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol . 2017 Oct 1;3(10):1335-1342. doi: 10.1001/jamaoncol.2017.0589.
3. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018 Dec;31(12):1770-1786. doi: 10.1038/s41379-018-0110-y. Epub 2018 Aug 23
4. Klimstra DS, Kloppell G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.16.
5. Strosberg JR, Benson AB, Huynh L et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist 2014; 19: 930-936 [PMID: 25096997 DOI: 10.1634/theoncologist.2014-0120]
6. Roberto GA, Rodrigues CMB, Peixoto RD et al. Gastric neuroendocrine tumor: A practical literature review. World J Gastrointest Oncol. 2020 Aug 15;12(8):850-856. doi: 10.4251/wjgo.v12.i8.850.
7. Gluckman CR, Metz DC. Gastric Neuroendocrine Tumors (Carcinoids). Curr Gastroenterol Rep 2019; 21: 13 [PMID: 30868284 DOI: 10.1007/s11894-019-0684-7]
8. Boyce M, Thomsen L. Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist. Scand J Gastroenterol 2015; 50: 550-559 [PMID: 25665655 DOI: 10.3109/00365521.2015.1009941]
9. https://www.nccn.org/home (2021) Neuroendocrine and Adrenal Tumors NCCN Guidelines Version: 3.2021 (12.09.2021 tarihinde https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf adresinden ulaşılmıştır.)
10. Kunz PL, Reidy-Lagunes D, Anthony LB et al. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013;42(4):557–77. https://doi.org/10.1097/MPA.0b013e31828e34a4
11. Jenny HE, Ogando PA, Fujitani K et al. Laparoscopic antrectomy: a safe and definitive treatment in managing type 1 gastric carcinoids. Am J Surg. 2016;211(4):778–82. https://doi.org/10.1016/j.amjsurg.2015.08.040.

12. Delle Fave G, O'Toole D, Sundin A et al. (Vienna Consensus Conference participants). ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 2016;103(2):119–24. https://doi.org/10.1159/000443168.
13. Arslan K, Hot S. (2016). Midenin Diğer Malign Neoplazmları. Mehmet Mihmanlı (ed), Mide Kanseri ve Cerrahi Tedavisi (s. 411-417). İstanbul: Tıbbi Yayınlar Merkezi
14. Park S, Choi MG, Kim KM et al. Lymphoepithelioma-like carcinoma: A distinct type of gastric cancer. J Surg Res. 2015 Apr;194(2):458-463. doi: 10.1016/j.jss.2014.12.005. Epub 2014 Dec 8.
15. Min BH, Tae CH, Ahn SM et al. Epstein-Barr virus infection serves as an independent predictor of survival in patients with lymphoepithelioma-like gastric carcinoma. Gastric Cancer. 2016 Jul;19(3):852-9. doi: 10.1007/s10120-015-0524-x. Epub 2015 Aug 12.
16. Liu L , Zhao H , Sheng L et al. Collision of Lymphoepithelioma-like Carcinoma with Diffuse Large B-cell Lymphoma of the Stomach: A Case Report. Anticancer Res. 2017 Aug;37(8):4569-4573. doi: 10.21873/anticanres.11855.
17. Liang P, Ren CH, Gao JB et al. CT findings and clinical features of Epstein–Barr virus-associated lymphoepithelioma-like gastric carcinoma. Medicine (Baltimore). 2019 Apr;98(14):e14839. doi: 10.1097/MD.0000000000014839.
18. Zhang ZR, Wu J, Li HW et al. Hepatoid adenocarcinoma of the stomach: Thirteen case reports and review of literatüre. World J Clin Cases. 2020 Mar 26;8(6):1164-1171. doi: 10.12998/wjcc.v8.i6.1164.
19. Xia R, Zhou Y, Wang Y et ali Hepatoid Adenocarcinoma of the Stomach: Current Perspectives and New Developments. Front Oncol. 2021 Apr 12;11:633916. doi: 10.3389/fonc.2021.633916. eCollection 2021.
20. Zeng XY, Yin YP, Xiao H et al. Clinicopathological Characteristics and Prognosis of Hepatoid Adenocarcinoma of the Stomach: Evaluation of a Pooled Case Series. Curr Med Sci (2018) 38:1054–61. doi: 10.1007/s11596-018-1983-1
21. Yamagata Y, Saito K, Ban S et al. The origin of p40-negative and CDX2- positive primary squamous cell carcinoma of the stomach: case report. World J Surg Oncol. 2019 Mar 19;17(1):53. doi: 10.1186/s12957-019-1594-8.
22. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.
23. Dong C, Jiang M, Tan Y et al. The clinicopathological features and prognostic factors of gastric squamous cell carcinoma. Medicine (Baltimore). 2016 Aug;95(34):e4720. doi: 10.1097/MD.0000000000004720.
24. Ge Y, Lin L, Ma X et al. Adenosquamous Carcinoma of the Stomach: A Population-based Study from the SEER Database. J Cancer. 2019 Sep 7;10(23):5705-5713. doi: 10.7150/jca.29162. eCollection 2019.
25. Li HS, Liu X, Zhang MY et al. Clinicopathologic characteristics, survival, and treatments for gastric adenosquamous carcinoma: a population-based study. Curr Oncol. 2020 Dec;27(6):e527-e536. doi: 10.3747/co.27.6337. Epub 2020 Dec 1.
26. Lee JH, Lee JK, Kang BD. Primary Gastric Choriocarcinoma Coexisting with Adenocarcinoma. Korean J Gastroenterol. 2019 Jun 25;73(6):350-354. doi: 10.4166/kjg.2019.73.6.350.
27. Hirotsu A, Hiramatsu Y, Kawata S et al. Rapid recurrence of primary gastric choriocarcinoma after complete resection. Int J Surg Case Rep. 2019;57:138-141. doi: 10.1016/j.ijscr.2019.03.045. Epub 2019 Mar 30.
28. Gurzu S, Copotoiu C, Tugui A et al. Primary gastric choriocarcinoma - a rare and aggressive tumor with multilineage differentiation: A case report. World J Clin Cases. 2019 Jul 26;7(14):1837-1843. doi: 10.12998/wjcc.v7.i14.1837.
29. Kobayashi A, Hasebe T, Endo Y et al. Primary gastric choriocarcinoma: two case reports and a pooled analysis of 53 cases. Gastric Cancer. 2005;8(3):178-85. doi: 10.1007/s10120-005-0332-9.

30. Zhu CC, Li MR, Lin TL et al. Sarcomatoid carcinoma of the stomach: A case report and literature review. Oncol Lett. 2015 Sep;10(3):1385-1389. doi: 10.3892/ol.2015.3460. Epub 2015 Jul 6.
31. Sato A, Oki E, Kohso H et al. Sarcomatoid carcinoma of the remnant stomach: report of a case. Surg Today. 2013 Mar;43(3):308-12. doi: 10.1007/s00595-012-0402-7. Epub 2012 Dec 14.
32. Li Y, Cui L, Chen Y et al. Carcinosarcoma and sarcomatoid carcinoma of the stomach Two case reports. Medicine (Baltimore). 2021 Mar 26;100(12):e24697. doi: 10.1097/MD.0000000000024697.
33. Ooe Y, Watanabe K, Hashimoto I et al. Title: pancreatic-type mixed acinar neuroendocrine carcinoma of the stomach: a case report and review of the literatüre. Diagn Pathol. 2021 Feb 2;16(1):11. doi: 10.1186/s13000-021-01070-x.
34. Kim KM, Kim CY, Hong SM et al. A primary pure pancreatic-type acinar cell carcinoma of the stomach: a case report. Diagn Pathol. 2017 Jan 19;12(1):10. doi: 10.1186/s13000-017-0601-z.
35. Yonenaga Y, Kurosawa M, Mise M et al. Pancreatic-type Acinar Cell Carcinoma of the Stomach Included in Multiple Primary Carcinomas. Anticancer Res. 2016 Jun;36(6):2855-64.
36. Yu H, Fang C, Chen L et al. Worse Prognosis in Papillary, Compared to Tubular, Early Gastric Carcinoma. J Cancer. 2017 Jan 1;8(1):117-123. doi: 10.7150/jca.17326. eCollection 2017.
37. Lauwers GY, Carneiro F, Graham DY, et al. Gastric carcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System. Lyon: IARC Press; 2010: 48-58.)
38. Ninomiya S, Sonoda K, Shiroshita H et al. Five-Year Survival after Surgery for Invasive Micropapillary Carcinoma of the Stomach. Case Rep Surg. 2013;2013:560712. doi: 10.1155/2013/560712. Epub 2013 Mar 27.
39. Uchida A, Ozawa M, Ueda Y et al Gastric adenocarcinoma of fundic gland mucosa type localized in the submucosa A case report. Medicine (Baltimore). 2018 Sep;97(37):e12341. doi: 10.1097/MD.0000000000012341.
40. Fan X, Yang XS, Bai P et al. Gastric adenocarcinoma of the fundic gland type A case report. Medicine (Baltimore). 2020 May 22;99(21):e20361. doi: 10.1097/MD.0000000000020361.
41. Benedict MA, Lauwers GY, Jain D. Gastric Adenocarcinoma of the Fundic Gland Type Update and Literature Review. Am J Clin Pathol. 2018 Apr 25;149(6):461-473. doi: 10.1093/ajcp/aqy019.
42. Takubo K, Honma N, Sawabe M, et al. Oncocytic adenocarcinoma of the stomach: parietal cell carcinoma. Am J Surg Pathol. 2002;26:458-465.)
43. Motta MP, Athanazio DA, Motta A et al. Parietal Cell (Oncocytic) Adenocarcinoma of the Stomach in a Female Patient: Superficial Spreading and Extensive Nodal Involvement. Int J Surg Pathol. 2008 Oct;16(4):447-9. doi: 10.1177/1066896908315750.
44. Mardi K. Oncocytic adenocarcinoma of the stomach: Parietal cell carcinoma. J Cancer Res Ther. Jan-Mar 2013;9(1):162-3. doi: 10.4103/0973-1482.110354.